Trial · NCT03226392
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 54
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | QAW039 150 mg | 5 | 352 | |
| other | Headache | Nervous system disorders | Placebo | 14 | 350 | |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | QAW039 150 mg | 46 | 352 | |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Placebo | 61 | 350 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | QAW039 150 mg | 2 | 352 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Placebo | 5 | 350 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | QAW039 150 mg | 3 | 352 | |
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Placebo | 5 | 350 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | QAW039 150 mg | 6 | 352 | |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Placebo | 4 | 350 | |
| other | Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | QAW039 150 mg | 3 | 352 | |
| other | Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | Placebo | 5 | 350 | |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | QAW039 150 mg | 1 | 352 | |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | Placebo | 4 | 350 | |
| serious | Acute myocardial infarction | Cardiac disorders | QAW039 150 mg | 0 | 352 | |
| serious | Acute myocardial infarction | Cardiac disorders | Placebo | 1 | 350 | |
| serious | Upper gastrointestinal haemorrhage | Gastrointestinal disorders | QAW039 150 mg | 1 | 352 | |
| serious | Upper gastrointestinal haemorrhage | Gastrointestinal disorders | Placebo | 0 | 350 | |
| serious | Non-cardiac chest pain | General disorders | QAW039 150 mg | 0 | 352 | |
| serious | Non-cardiac chest pain | General disorders | Placebo | 1 | 350 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03226392/events?page=2